Semi-Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for the Combination Use of Dexamethasone and Gemcitabine in Breast Cancer

Journal of Pharmaceutical Sciences

Volumn 104, Issue 12, 2015, Pages 4399-4408

  Yuan, Yin ^a   Zhou, Xuan ^a   Ren, Yupeng ^a   Zhou, Shupei ^a   Wang, Lijie ^a   Ji, Shuangmin ^a   Hua, Ming ^a   Li, Liang ^a,b   Lu, Wei ^a,b   Zhou, Tianyan ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

cancer chemotherapy; drug interaction; in silico modeling; pharmacokinetic pharmacodynamic models; simulation

Indexed keywords

DEXAMETHASONE; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG POTENCY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; COMBINATION DRUG THERAPY; DISEASE MODEL; DOSE RESPONSE; DRUG POTENTIATION; DRUG SCREENING; NUDE MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DEOXYCYTIDINE; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MCF-7 CELLS; MICE, INBRED BALB C; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84954364466     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24629     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. 2011. Global cancer statistics. CA Cancer J Clin 61 (2): 69-90.
2. Wu S, Guo J, Wei W, Zhang J, Fang J, Beebe SJ,. 2014. Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine. Cancer Cell Int 14 (1): 98.
3. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W,. 1991. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51 (22): 6110-6117.
4. Petrioli R, Roviello G, Fiaschi AI, Laera L, Marrelli D, Roviello F, Francini E,. 2015. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: A randomized phase II study. Cancer Chemother Pharmacol 75 (4): 683-690.
5. O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, Winer EP,. 2014. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 32 (34): 3840-3847.
6. Honeywell RJ, Ruiz van Haperen VW, Veerman G, Smid K, Peters GJ,. 2015. Inhibition of thymidylate synthase by 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine) and its metabolite 2′,2′-difluoro-2′-deoxyuridine. Int J Biochem Cell Biol 60C: 73-81.
7. Dranitsaris G, Beegle N, Kalberer T, Blau S, Cox D, Faria C,. 2015. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting. J Oncol Pharm Pract 21 (3): 170-177.
8. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J,. 2008. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26 (12): 2013-2019.
9. Poon C, He C, Liu D, Lu K, Lin W,. 2015. Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. J Control Release 201C: 90-99.
10. Gong H, Jarzynka MJ, Cole TJ, Lee JH, Wada T, Zhang B, Gao J, Song WC, DeFranco DB, Cheng SY, Xie W,. 2008. Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. Cancer Res 68 (18): 7386-7393.
11. Lewis KM, Harford-Wright E, Vink R, Ghabriel MN,. 2013. NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer. Anti-Cancer Drugs 24 (4): 344-354.
12. Villeneuve J, Galarneau H, Beaudet MJ, Tremblay P, Chernomoretz A, Vallieres L,. 2008. Reduced glioma growth following dexamethasone or anti-angiopoietin 2 treatment. Brain Pathol 18 (3): 401-414.
13. Bavaresco L, Bernardi A, Braganhol E, Wink MR, Battastini AM,. 2007. Dexamethasone inhibits proliferation and stimulates ecto-5′-nucleotidase/CD73 activity in C6 rat glioma cell line. J Neuro-Oncol 84 (1): 1-8.
14. Coimbra M, Rijcken CJ, Stigter M, Hennink WE, Storm G, Schiffelers RM,. 2012. Antitumor efficacy of dexamethasone-loaded core-crosslinked polymeric micelles. J Control Release 163 (3): 361-367.
15. Wang H, Wang Y, Rayburn ER, Hill DL, Rinehart JJ, Zhang R,. 2007. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: Potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol 30 (4): 947-953.
16. Geng Y, Wang J, Jing H, Wang HW, Bao YX,. 2014. Inhibitory effect of dexamethasone on Lewis mice lung cancer cells. Genetics Mol Res 13 (3): 6827-6836.
17. Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K,. 2006. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 12 (10): 3003-3009.
18. Li M, Li H, Cheng X, Wang X, Li L, Zhou T, Lu W,. 2013. Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine. Pharm Res 30 (5): 1400-1408.
19. Khatri A, Brundage RC, Hull JM, Williams BW, Yee D, Kirstein MN,. 2012. Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine. AAPS J 14 (1): 1-9.
20. Yuan Y, Zhou X, Li J, Ye S, Ji X, Li L, Zhou T, Lu W,. 2015. Development and validation of a highly sensitive LC-MS/MS method for the determination of dexamethasone in nude mice plasma and its application to a pharmacokinetic study. Biomed Chromatogr 29 (4): 578-583.
21. Immordino ML, Brusa P, Rocco F, Arpicco S, Ceruti M, Cattel L,. 2004. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release 100 (3): 331-346.
22. Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW, Sampath D, Wallin JJ,. 2010. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 38 (9): 1436-1442.
23. Koch G, Walz A, Lahu G, Schropp J,. 2009. Modeling of tumor growth and anticancer effects of combination therapy. J Pharmacokinet Pharmacodyn 36 (2): 179-197.
24. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M,. 2004. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64 (3): 1094-1101.
25. Lobo ED, Balthasar JP,. 2002. Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro. AAPS PharmSci 4 (4): E42.
26. Drebert Z, Bracke M, Beck IM,. 2015. Glucocorticoids and the non-steroidal selective glucocorticoid receptor modulator, compound A, differentially affect colon cancer-derived myofibroblasts. J Steroid Biochem Mol Biol 149: 92-105.
27. Jusko WJ,. 1971. Pharmacodynamics of chemotherapeutic effects: Dose-time-response relationships for phase-nonspecific agents. J Pharm Sci 60 (6): 892-895.
28. Savic RM, Jonker DM, Kerbusch T, Karlsson MO,. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34 (5): 711-726.
29. Holford N,. Immediate time course of drug effect. Available at: http://holford.fmhs.auckland.ac.nz/docs/immediate-time-course-of-drug-effect.pdf.
30. Leggas M, Kuo KL, Robert F, Cloud G, deShazo M, Zhang R, Li M, Wang H, Davidson S, Rinehart J,. 2009. Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: Effect on chemotherapy toxicity and efficacy. Cancer Chemother Pharmacol 63 (4): 731-743.
31. Higgins B, Kolinsky K, Smith M, Beck G, Rashed M, Adames V, Linn M, Wheeldon E, Gand L, Birnboeck H, Hoffmann G,. 2004. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anti-Cancer Drugs 15 (5): 503-512.
32. Rocchetti M, Simeoni M, Pesenti E, De Nicolao G, Poggesi I,. 2007. Predicting the active doses in humans from animal studies: A novel approach in oncology. Eur J Cancer 43 (12): 1862-1868.
33. Higgins B, Glenn K, Walz A, Tovar C, Filipovic Z, Hussain S, Lee E, Kolinsky K, Tannu S, Adames V, Garrido R, Linn M, Meille C, Heimbrook D, Vassilev L, Packman K,. 2014. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clin Cancer Res 20 (14): 3742-3752.